Immuneering Corp (IMRX)
Healthcare
Biotechnology
4.20 $
+1.0%
vs. previous close
Closing price · As of: 3. Aug 2026
Immuneering Corp (IMRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -18 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11 | -12 | -12 | -15 | -12 | -13 | -15 | -14 | -9.4 | -12 | -9.8 | -18 | -50 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.5 | |
| 1.3 | 1.5 | 1.6 | 1.5 | 1.7 | 1.6 | 1.7 | 1.7 | 1.5 | 4,670 | 1.6 | 1,637 | 6,310 | |
| 1.3 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | -0.8 | 1.9 | -2.7 | 0.7 | -0.7 | 1.7 | -0.9 | 3.3 | 1.4 | 0.1 | -6.4 | -1.7 | |
| 0.1 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | |
| 9.2 | -24 | 3.1 | 21 | 5.0 | -5.4 | 5.5 | 0.0 | 0.0 | 0.0 | -89 | -63 | -152 | |
| 28 | – | – | – | – | 375 | – | 134 | – | 422 | – | 170 | – | |
| 28 | 0.0 | 0.0 | 1.0 | 0.0 | 4.4 | 0.0 | 14 | -0.1 | 213 | -0.4 | 0.2 | 213 | |
| 27 | -36 | -8.6 | 6.9 | -6.6 | -15 | -9.1 | -0.3 | -9.5 | 201 | -99 | -81 | 11 | |
| -11 | -12 | -12 | -16 | -12 | -13 | -15 | -14 | -9.4 | -12 | -10.0 | -19 | -50 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.